All In Biotech

Drug Trial Radar · NCT07542756

A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia

Sequential Multiple Assignment Randomized Trial Comparing Commonly Prescribed and Over the Counter Medications for the Treatment of Insomnia in Adults

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Jan 1, 2032

Study completion Jan 1, 2032

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the relative effectiveness, safety, and durability of the most commonly used prescription (zolpidem, trazodone) and over-the-counter (OTC) (melatonin, diphenhydramine) medications for insomnia, as well as a less commonly used prescription that may have a better risk/benefit profile (doxepin).

Conditions

  • Insomnia
  • Insomnia Disorder
  • Chronic Insomnia
  • Chronic Insomnia Disorder

Interventions

  • Sleep Hygiene EducationOther

    Standard behavioral and environmental recommendations aimed at promoting healthy sleep

  • Melatonin IR, 3 mgDietary supplement

    Immediate release formulation of melatonin, once nightly 30 minutes prior to bed

  • Melatonin IR, 5 mgDietary supplement

    Immediate release formulation of melatonin, once nightly 30 minutes prior to bed

  • Diphenhydramine, 25 mgDrug

    Diphenhydramine 25 mg, once nightly 30 minutes prior to bed. Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.

  • Diphenhydramine, 50 mgDrug

    Diphenhydramine, 50 mg, once nightly 30 minutes prior to bed. Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.

  • Doxepin, 3 mgDrug

    Doxepin, 3 mg, once nightly 30 minutes prior to bed

  • Doxepin, 6 mgDrug

    Doxepin, 6 mg, once nightly 30 minutes prior to bed

  • Trazodone, 50 mgDrug

    Trazodone, 50 mg, once nightly 30 minutes prior to bed

  • Trazodone, 100 mgDrug

    Trazodone, 100 mg, once nightly 30 minutes prior to bed

  • PlaceboDrug

    Placebo, once nightly 30 minutes prior to bed

  • Zolpidem, 5 mgDrug

    Zolpidem, 5 mg, once nightly 30 minutes prior to bed

  • Zolpidem, 10 mgDrug

    Zolpidem, 10 mg, once nightly 30 minutes prior to bed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative treatment response rates during acute (1-month) treatment phaseTime frame: From treatment initiation to 1 month after treatment initiation
  2. Relative safety and tolerability based on side effects during acute (1-month) treatment phaseTime frame: From treatment initiation to 1 month after treatment initiation
  3. Relative effects on daytime symptoms and function during acute (1-month) treatment phaseTime frame: From treatment initiation to 1 month after treatment initiation
  4. Durability of treatment response during longer-term maintenance (1-6 months) treatment phaseTime frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
  5. Relative safety and tolerability based on side effects during longer-term maintenance (1-6 months) phaseTime frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation
  6. Durability of effects on daytime symptoms and function during longer-term maintenance (1-6 months) phaseTime frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.